Epidemiology and Risks for Infection Following Cytoreductive Surgery and Hyperthermic Intra-Peritoneal Chemotherapy at an Australian Centre
Background. Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) is associated with improved cancer survival but increased risk of infection in patients with abdominal-pelvic malignancy. We evaluated risks and characteristics of infectious outcomes at an Australian cancer centre.
Methods. Patients undergoing CRS-HIPEC between January 2016 and November 2017 at Peter MacCallum Cancer Centre were retrospectively reviewed. Malignancy type, comorbidities, perioperative risk factors, and infectious complications were captured, using standardized definitions for surgical site infection. Association between risk factors and infection outcomes was evaluated by logistic regression modeling.
Results. Sixty-nine patients underwent CRS-HIPEC, predominantly for colorectal cancer and pseudomyxoma peritonei. Overall, 32 (46.3%) experienced an infectious complication, including infections at surgical site (16), respiratory tract (6), urinary tract (5), Clostridium difficile (2), and post-operative sepsis (10). In most, infection onset was within 7 days post-operatively. Median length of hospitalisation was 20 days for patients with infection, compared with 8 days for those without (P = 0.000). Of variables potentially associated with infection at surgical site, small bowel resection (OR 5.56, 95% confidence interval [CI] 1.09-28.19; P = 0.039) and number of resected viscera (OR 1.71, 95% CI 1.05-2.76; P = 0.029) were significantly associated with infection on univariate analysis.
Conclusion. We demonstrate a significant burden of early infective complications in patients undergoing CRS-HIPEC, including surgical and non-surgical site infections. Findings support the need for multimodal programs to reduce the risk of a broad range of infections in this population. Higher risk subgroups, including those with small bowel resection and increased number of resected viscera, may benefit from enhanced monitoring.
Disclosures. All authors: No reported disclosures. Friday, October 5, 2018: 12:30 PM Background. CDI is a bacterial infection that typically occurs after the use of broad-spectrum antibiotics. Older adults are particularly susceptible to this potentially deadly disease and at higher risk of recurrence.
Evaluation of Fecal Microbiota Transplant (FMT) in Elderly Patients
Methods. The study was approved by the hospital's IRB. Patients 65 years of age and older with refractory or recurrent CDI who received FMT administered via colonoscopy or oral capsules were included. Patients with severe-complicated infection were excluded and ineligible to receive FMT. Each patient was evaluated 8 weeks post-transplant to assess for sustained clinical response and adverse events. Data collection included patient demographics, number of recurrent CDI episodes, CDI severity, previous antibiotic treatment regimens, clinical cure, adverse events, and donor information.
Results. Thirty-five patients were enrolled (23 colonoscopy FMT vs. 13 oral capsule FMT). One patient received FMT via colonoscopy twice. Mean age was 77 years , female 60%, median recurrent episode was 3, and median CDI severity score was 2. Total success rate was 69.4% (25/36), 60.9% (14/23) via colonoscopy vs. 84.6% (11/13) via capsule. Total success rate for female 67% vs. 73% male and age group of 65-75 was 60% vs. 76% in age group 75+. For capsules only, cure rate was 80% in female vs. 100% in male and 75% in 65-75 age group vs. 89% in patients older than 75 while in colonoscopy only group, success rate was 55% in female vs. 67% in males and 46% in 65-75 age group vs. 67% in age group 75+. There did not seem to be a correlation between FMT donor and success rate. No serious adverse events were reported in the study population.
Conclusion. FMT may be considered a potentially useful therapy for the treatment of refractory or recurrent CDI cases in patients 65 years of age and older. Further studies are needed to confirm the above findings.
Older adults are particularly susceptible to this potentially deadly disease Disclosures. All authors: No reported disclosures. Friday, October 5, 2018: 12:30 PM Background. Cholera has caused seven global pandemics, including the current one which has been ongoing since 1961. A systematic review of risk factors for symptomatic cholera infection has not been previously published.
Individual and Household Risk Factors for Symptomatic
Methods. In accordance with PRISMA guidelines, we performed a systematic review and meta-analysis of individual and household risk factors for symptomatic cholera infection.
Results. We identified 110 studies eligible for inclusion in qualitative synthesis. Factors associated with symptomatic cholera that were eligible for meta-analysis included education less than secondary level (summary OR 2.64, 95% CI 1.41-4.92, I 2 = 8%), unimproved water source (summary OR 4.78, 95% CI 3.02-7.57, I 2 = 49%), open container water storage (summary OR 2.51, 95% CI 1.57-4.01, I 2 = 33%), consumption of food outside the home (summary OR 5.02, 95% CI 2.34-10.76, I 2 = 61%), household contact with cholera (summary OR 3.99, 95% CI 2.03-7.87, I 2 = 89%), water treatment (summary OR 0.22, 95% CI 0.13-0.36, I 2 = 37%), and handwashing (summary OR 0.17, 95% CI 0.10-0.30, I 2 = 37%). Other notable associations with symptomatic infection included income/ wealth, blood group, gastric acidity, infant breastfeeding status, and HIV infection.
Conclusion. We identified potential risk factors for symptomatic cholera infection including environmental characteristics, socioeconomic factors, and intrinsic patient factors. Ultimately, a combination of interventional approaches targeting various groups with risk-adapted intensities may prove to be the optimal strategy for cholera control.
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